Compare SEVN & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEVN | SENS |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Machinery/Components |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 213.2M |
| IPO Year | 2008 | 2014 |
| Metric | SEVN | SENS |
|---|---|---|
| Price | $8.43 | $5.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $10.50 | ★ $18.38 |
| AVG Volume (30 Days) | 105.1K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | $16,389,000.00 |
| Revenue This Year | $27.75 | $74.15 |
| Revenue Next Year | $4.06 | $58.60 |
| P/E Ratio | $43.63 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $7.90 | $0.41 |
| 52 Week High | $12.85 | $8.75 |
| Indicator | SEVN | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 46.87 |
| Support Level | $8.33 | $5.26 |
| Resistance Level | $8.95 | $7.16 |
| Average True Range (ATR) | 0.17 | 0.49 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 80.70 | 39.66 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.